Sabra Health Care REIT, Inc.

NasdaqGS:SBRA Stock Report

Mkt Cap: US$3.1b

We’ve recently updated our valuation analysis.

Sabra Health Care REIT Valuation

Is SBRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SBRA?

Other financial metrics that can be useful for relative valuation.

SBRA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue13.1x
Enterprise Value/EBITDA22.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SBRA's PS Ratio compare to its peers?

The above table shows the PS ratio for SBRA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average8.7x
NHI National Health Investors
8.9x10.6%US$2.5b
DOC Physicians Realty Trust
6.9x2.7%US$3.7b
LTC LTC Properties
9x8.2%US$1.5b
CTRE CareTrust REIT
9.8x9.3%US$1.9b
SBRA Sabra Health Care REIT
7.3x7.7%US$3.1b

Price-To-Sales vs Peers: SBRA is good value based on its Price-To-Sales Ratio (7.3x) compared to the peer average (8.7x).


Price to Earnings Ratio vs Industry

How does SBRA's PE Ratio compare vs other companies in the US REITs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a4.8%
n/an/an/a

Price-To-Sales vs Industry: SBRA is expensive based on its Price-To-Sales Ratio (7.3x) compared to the US REITs industry average (5x)


Price to Sales Ratio vs Fair Ratio

What is SBRA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SBRA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.3x
Fair PS Ratio4.1x

Price-To-Sales vs Fair Ratio: SBRA is expensive based on its Price-To-Sales Ratio (7.3x) compared to the estimated Fair Price-To-Sales Ratio (4.1x).


Share Price vs Fair Value

What is the Fair Price of SBRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SBRA ($13.31) is trading below our estimate of fair value ($26.4)

Significantly Below Fair Value: SBRA is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SBRA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$13.31
US$14.08
+5.8%
10.2%US$18.00US$12.00n/a13
Jan ’24US$12.43
US$14.38
+15.7%
10.4%US$18.00US$12.00n/a13
Dec ’23US$12.82
US$14.84
+15.8%
10.9%US$18.00US$12.00n/a14
Nov ’23US$13.61
US$15.45
+13.5%
12.3%US$20.00US$12.00n/a14
Oct ’23US$13.12
US$16.25
+23.9%
9.0%US$20.00US$14.00n/a15
Sep ’23US$14.77
US$16.18
+9.6%
9.2%US$20.00US$14.00n/a15
Aug ’23US$15.57
US$15.22
-2.3%
5.7%US$17.00US$14.00n/a15
Jul ’23US$14.29
US$15.25
+6.7%
5.6%US$17.00US$14.00n/a15
Jun ’23US$13.94
US$15.64
+12.2%
6.7%US$18.00US$14.00n/a14
May ’23US$11.68
US$15.77
+35.0%
7.0%US$18.00US$14.00n/a14
Apr ’23US$15.10
US$15.77
+4.4%
7.4%US$18.00US$14.00n/a14
Mar ’23US$13.01
US$16.02
+23.1%
11.3%US$21.00US$13.50n/a14
Feb ’23US$13.32
US$16.78
+26.0%
12.6%US$21.00US$13.50n/a15
Jan ’23US$13.54
US$17.34
+28.1%
10.6%US$21.00US$13.50US$12.4314
Dec ’22US$12.53
US$17.66
+40.9%
8.6%US$21.00US$15.25US$12.8214
Nov ’22US$14.95
US$18.71
+25.2%
8.4%US$21.00US$16.00US$13.6114
Oct ’22US$14.94
US$19.14
+28.1%
7.9%US$21.00US$16.00US$13.1214
Sep ’22US$16.32
US$19.43
+19.0%
10.1%US$24.00US$16.00US$14.7714
Aug ’22US$18.59
US$19.79
+6.4%
9.2%US$24.00US$17.00US$15.5714
Jul ’22US$18.40
US$19.71
+7.1%
9.1%US$24.00US$17.00US$14.2914
Jun ’22US$18.03
US$19.64
+8.9%
8.9%US$24.00US$17.00US$13.9414
May ’22US$18.17
US$18.77
+3.3%
11.0%US$24.00US$15.75US$11.6814
Apr ’22US$18.14
US$18.63
+2.7%
11.4%US$24.00US$15.75US$15.1014
Mar ’22US$17.56
US$18.52
+5.5%
11.4%US$24.00US$15.75US$13.0114
Feb ’22US$17.33
US$18.02
+4.0%
11.8%US$24.00US$15.00US$13.3214
Jan ’22US$17.37
US$17.39
+0.1%
14.5%US$24.00US$12.75US$13.5414

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies